All patients were dosed with therapies manufactured in Lonza's Cocoon Platform, an automated, customizable, patient-scale cell therapy platform that streamlines manufacturing to improve process efficiency and reliability.
'We have been successfully manufacturing Sheba's CD19 CAR-T therapy in the Cocoon Platform and observing positive clinical outcomes, which is exciting and promising. We are proving that the Cocoon Platform can be used to replace open, manual manufacturing processes which are in most cases expensive and difficult to scale. The Cocoon Platform is showing significant advantages when used for centralized, decentralized, and point-of-care manufacturing. We continue to gain traction in the market, with the aim of revolutionizing the production of patient-scale cell therapy and making these lifesaving therapies available to more patients in need.'
Professor Dror Harats, Deputy Director for Research and Development and Acting Director for Clinical Trials,
'This unique effort initiated between a leading biotechnology company and Sheba is a prime example of how we are dealing with today's and tomorrow's medicine. The collaborative relationship between innovative medical technologies and medicine enables leading hospitals such as Sheba to create breakthrough personalized medical treatments that are amongst the best within the world of biomed.'
The collaboration between
The data demonstrates the Cocoon Platform's flexibility and capability to manufacture immunotherapies, compared with manual processes. As there are several commercially available CAR-T cell therapies that are approved in
Contact:
Muenchensteinerstrasse 38
CH-4002
Tel: +41 61 316 81 11
Fax: +41 61 316 91 11
(C) 2021 Electronic News Publishing, source